Methods for inhibiting endothelial cell and fibrinogen mediated inflammation using fibrinogen specific antibodies
US6737058B2 · kind B2 · utility
4Cited by
4References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 24, 2001 |
| Grant date | May 18, 2004 |
| Priority date | — |
| Expiry date | Aug 27, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention contemplates therapeutic compositions containing a fibrinogen homolog capable of binding to endothelial cells in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Also described are therapeutic compositions containing an ICAM-1 homolog capable of binding to fibrinogen in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Methods of inhibiting endothelial cell and fibrinogen mediated inflammation within a patient by administering a homolog of this invention are also contemplated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.